Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
3 min read
At the annual SITC meeting, Nimbus Therapeutics unveiled encouraging initial results from a clinical study on an HPK1 inhibitor for solid tumors
6 November 2023
Nimbus Therapeutics, LLC has now shared preliminary findings from its ongoing Phase 1/2 trial of NDI-101150, an HPK1 small-molecule inhibitor.
Valuable Targets
6 min read
Analysis on the Clinical Research Progress of Factor Xa Inhibitor
6 November 2023
Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.
Latest Hotspot
3 min read
At SITC 2023, INmune Bio Inc. shared preclinical findings indicating INB03 as an innate immune checkpoint suppressor that reduces SIRPα
6 November 2023
Immunology firm, INmune Bio, Inc. will present its findings on the use of INB03 in managing high-risk MUC4 expressing HER2+ breast cancer. INB03 is a dominant-negative suppressor of soluble TNF.
Drug Insights
4 min read
A Comprehensive Review of Hydrocortisone Sodium Succinate's R&D Innovations and Drug Target Mechanism
6 November 2023
This article summarized the latest R&D progress of Hydrocortisone Sodium Succinate, the Mechanism of Action for Hydrocortisone Sodium Succinate, and the drug target R&D trends for Hydrocortisone Sodium Succinate.
Latest Hotspot
4 min read
Sarepta Therapeutics Releases Preliminary Findings of EMBARK, a Critical Global Trial on ELEVIDYS, a Gene Treatment for Duchenne Muscular Dystrophy
6 November 2023
Sarepta Therapeutics, Inc. shared initial results from EMBARK, a global Phase 3 trial evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in Duchenne muscular dystrophy patients aged 4-7.
Drug Insights
4 min read
Pharmaceutical Insights: Ibudilast's R&D Progress and its Mechanism of Action on Drug Target
6 November 2023
This article summarized the latest R&D progress of Ibudilast, the Mechanism of Action for Ibudilast, and the drug target R&D trends for Ibudilast.
Valuable Targets
7 min read
Advances in Clinical Research on Cyclin-dependent Kinase Inhibitor
6 November 2023
CDKs or cyclin-dependent kinase,are a group of enzymes that play a crucial role in regulating the cell cycle in the human body.
Drug Insights
4 min read
Exploring Ipratropium bromide/Albuterol sulfate's Revolutionary R&D Successes
6 November 2023
This article summarized the latest R&D progress of Ipratropium bromide/Albuterol sulfate, the mechanism of action for Ipratropium bromide/Albuterol sulfate, and the drug target R&D trends for Ipratropium bromide/Albuterol sulfate.
Latest Hotspot
3 min read
SparX Biopharma declares FDA approval of IND application for SPX-303, an initial human test of anti-LILRB2/PD-L1 antibody medication
6 November 2023
SparX Biopharmaceutical Corp. happily announces FDA approval of its IND application for SPX-303, a key development in powered antibody therapies and a leading anti-LILRB2/PD-L1 bispecific antibody drug candidate.
Bio Sequence
3 min read
The Competitive Landscape Behind the FDA-approved New Treatment for Biliary Tract Cancer, Keytruda
6 November 2023
According to the Patsnap Bio Sequence Database, the top 10 applicants for the Keytruda patent are Novartis AG with 438 applications, Merck Sharp & Dohme Corp. with 350 applications, and Merck Sharp & Dohme LLC with 299 applications.
Valuable Targets
6 min read
Analysis on the Research Progress of Dihydrofolate Reductase Inhibitor
6 November 2023
DHFR, or dihydrofolate reductase, is an indispensable enzyme required for the survival of most prokaryotic and eukaryotic cells as it is involved in the biosynthesis of essential cellular components.
Drug Insights
4 min read
Decoding Lanadelumab: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
6 November 2023
This article summarized the latest R&D progress of Lanadelumab, the Mechanism of Action for Lanadelumab, and the drug target R&D trends for Lanadelumab.